Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is positioning in an era where point-of-care (“POC”) testing offers numerous benefits, including faster results, lower costs, improved monitoring and medication adherence, and more. In the shift to a more decentralized testing approach, Avricore is taking part in this disruption through its POCT platform, HealthTab(TM), found at select community pharmacies. “HealthTab combines point-of-care analyzers that screen for over 20 biomarkers with a consumer-facing interface that displays results,” reads a recent article. “The analyzers screen for more than 20 biomarkers associated with select chronic and infectious diseases and communicate them in real-time with patients and trained health care professionals. In a November 23 announcement, Avricore celebrated the signing of a distribution agreement with Abbott that expanded its platform’s capabilities to better support patients with vital information about their renal function.” Avricore CEO Hector Bremner was quoted on the move as saying, “Understanding renal function in patients at risk from or already living with chronic disease is critical. With i-STAT Alinity and its associated test for creatinine, health care professionals can obtain results in approximately two minutes to detect elevated levels of creatinine that are associated with abnormal renal function.”
To view the full article, visit https://ibn.fm/A38CS
About Avricore Health Inc.
Avricore Health is a pharmacy service innovator focused on acquiring and developing early stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab(TM), (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies. For more information about the company, visit www.AvricoreHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
